More M&A Deals Could Boost Biotech ETFs

By
December 12, 2012
Share:

Amgen’s $415 million acquisition of DeCode suggests big-pharma will transition from blockbuster drugs to specialized medicines that target specific areas of the human body, a possibility that could bode well for the biotech sector and its ETFs, according to an article on ETF Trends.

The pursuit for targeted drugs could also benefit from the Obama administration’s push toward health care reform, as the extra insurance coverage would boost demand for medicines, the article said.

For investors seeking a doorway into biotech investments, consider these sector-covering ETFs as a starting point:

  • Market Vectors Biotech ETF (NYSEArca: BBH)
  • iShares Nasdaq Biotechnology ETF (NYSEArca: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT)

 

Head over to ETFtrends.com to learn more about ETFs within the biotech sector.

ETF.COM CHANNELS

Learn why commodity ETFs are an essential part of a diversified portfolio with our Commodity ETFs channel.

Learn why bond ETFs are an essential part of a diversified portfolio with our bond ETF channel.

ETF DAILY DATA

The biotech ETF was the biggest loser in terms of outflows on Friday, Feb. 5.

Vanguard ETF assets ticked up on Friday, Feb. 5.

ETF.COM ANALYST BLOGS

By Dave Nadig

For all the hype, here’s an example of an ETF working just as it should.

By Matt Hougan

Here's why you should attend the largest ETF conference in the world next month.

By Dave Nadig

Barclays built in a premium to this exchange-traded note, so back away.

By Sumit Roy

Why this probably isn't the start of a bear market.

ETF INDUSTRY PERSPECTIVE

By Heidi Richardson

Opportunities in Germany and the eurozone.

By Shirish Malekar

How to protect your portfolio with liquid alts.